{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:15:41Z","timestamp":1791976541107,"version":"4.4.0"},"reference-count":67,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DDDT"],"DOI":"10.2147\/dddt.s315172","type":"journal-article","created":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T01:50:13Z","timestamp":1706925013000},"page":"291-306","source":"Crossref","is-referenced-by-count":18,"title":["Developments in the Management of Growth Hormone Deficiency: Clinical Utility of Somapacitan"],"prefix":"10.2147","volume":"Volume 18","author":[{"given":"Bradley","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3128-5574","authenticated-orcid":true,"given":"Jo","family":"Blair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Horikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Linglart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8169-2728","authenticated-orcid":true,"given":"Kevin","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,2]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"C1","DOI":"10.1530\/EJE-16-0111","volume":"174","author":"Christiansen","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1742-1241.2007.01630.x","volume":"62","author":"Cramer","year":"2008","journal-title":"Int J Clin Pract"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.eprac.2022.02.013","volume":"28","author":"Loftus","year":"2022","journal-title":"Endocr Pract"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1159\/000437305","volume":"84","author":"Lass","year":"2015","journal-title":"Horm Res Paediatr"},{"key":"ref5","first-page":"e9","volume":"6","author":"Miller","year":"2014","journal-title":"Am J Pharm Benefits"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1014743","DOI":"10.3389\/fendo.2022.1014743","volume":"13","author":"Loftus","year":"2022","journal-title":"Front Endocrinol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s11102-020-01046-y","volume":"23","author":"Kreitschmann-Andermahr","year":"2020","journal-title":"Pituitary"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"248","DOI":"10.30476\/IJCBNM.2019.81303.0","volume":"7","author":"Danielson","year":"2019","journal-title":"Int J Community Based Nurs Midwifery"},{"key":"ref9","unstructured":"Food and Drug Administration. FDA approves weekly therapy for adult growth hormone deficiency. Available from: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-weekly-therapy-adult-growth-hormone-deficiency. Accessed March 24, 2023."},{"key":"ref10","unstructured":"European Medicines Agency. Sogroya European public assessment report (EPAR). Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/sogroya. Accessed March 24, 2023."},{"key":"ref11","unstructured":"Pharmaceutical and Medical Devices Agency. Report on investigation results. Available from: https:\/\/www.pmda.go.jp\/files\/000246397.pdf. Accessed 24, March 2023."},{"key":"ref12","unstructured":"GlobalNewswire. Novo Nordisk A\/S: Sogroya\u00ae data show potential as once-weekly treatment in children living with growth hormone deficiency. Available from: https:\/\/www.globenewswire.com\/news-release\/2022\/06\/12\/2460802\/0\/en\/Novo-Nordisk-A-S-Sogroya-data-show-potential-as-once-weekly-treatment-in-children-living-with-growth-hormone-deficiency.html. Accessed March 24, 2023."},{"key":"ref13","unstructured":"Novo Nordisk. FDA approves once-weekly Sogroya\u00ae for the treatment of children living with growth hormone deficiency. Available from: https:\/\/www.novonordisk-us.com\/content\/nncorp\/us\/en_us\/media\/news-archive\/news-details.html?id=166098. Accessed May 30, 2023."},{"key":"ref14","unstructured":"Novo Nordisk. Sogroya(R) somapacitan-beco injection 10 mg pen. Available from: https:\/\/www.novo-pi.com\/sogroya.pdf. Accessed April 13, 2023."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.2147\/DDDT.S336285","volume":"16","author":"Miller","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"ref16","unstructured":"European Medicines Agency. Ngenla(R) European public assessment report (EPAR). Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/ngenla-epar-public-assessment-report_en.pdf. Accessed January 12, 2023."},{"key":"ref17","unstructured":"European Medicines Agency. Sogroya SmPC. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/sogroya-epar-product-information_en.pdf. Accessed August 25, 2023."},{"key":"ref18","unstructured":"European Medicines Agency. Lonapegsomatropin: SmPC. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/skytrofa-previously-lonapegsomatropin-ascendis-pharma-epar-product-information_en.pdf.Accessed January 12, 2023."},{"key":"ref19","unstructured":"Food and Drug Administration. Highlights of prescribing information: Skytrofa. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761177s001lbl.pdf. Accessed January 12, 2023."},{"key":"ref20","unstructured":"European Medicines Agency. Lonapegsomatropin(R) European public assessment report (EPAR). Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/lonapegsomatropin-ascendis-pharma-epar-public-assessment-report_en.pdf.Accessed.Accessed January 12, 2023."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1210\/jc.2015-1991","volume":"101","author":"H\u00f8jby Rasmussen","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"ref22","unstructured":"ClinicalTrials.gov. A trial to investigate long term efficacy and safety of lonapegsomatropin in adults with growth hormone deficiency: NCT05171855. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05171855. Accessed January 12, 2023."},{"key":"ref23","unstructured":"ClinicalTrials.gov. A phase 3, multicenter study to evaluate The efficacy and safety of MOD-4023 in adults with growth hormone deficiency. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01909479. Accessed May 30, 2023."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"106030","DOI":"10.1016\/j.ejps.2021.106030","volume":"167","author":"Helleberg","year":"2021","journal-title":"Eur J Pharm Sci"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1021\/acs.biochem.0c00019","volume":"59","author":"Johansson","year":"2020","journal-title":"Biochemistry"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2147\/VHRM.S4039","volume":"5","author":"Deacon","year":"2009","journal-title":"Vasc Health Risk Manag"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1023\/B:PHAM.0000036926.54824.37","volume":"21","author":"Havelund","year":"2004","journal-title":"Pharm Res"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3389\/fendo.2019.00155","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front Endocrinol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.3390\/ijms21041181","volume":"21","author":"Petersen","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s40262-021-00990-7","volume":"60","author":"Bentz Damholt","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e1358","DOI":"10.1210\/clinem\/dgaa049","volume":"105","author":"Johannsson","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/cen.14273","volume":"93","author":"Otsuka","year":"2020","journal-title":"Clin Endocrinol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"E1819","DOI":"10.1210\/jc.2014-1702","volume":"99","author":"H\u00f8jby Rasmussen","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1530\/EJE-17-1073","volume":"178","author":"Johannsson","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11102-022-01283-3","volume":"26","author":"Takahashi","year":"2023","journal-title":"Pituitary"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e1847","DOI":"10.1210\/clinem\/dgz310","volume":"105","author":"S\u00e4vendahl","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1210\/clinem\/dgab928","volume":"107","author":"S\u00e4vendahl","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1210\/clinem\/dgad183","volume":"108","author":"S\u00e4vendahl","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1210\/clinem\/dgac513","volume":"107","author":"Miller","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1210\/clinem\/dgad394","volume":"108","author":"Miller","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"ref41","unstructured":"ClinicalTrials.gov. A research study in Chinese children with a low level of hormone to grow. Treatment is somapacitan once a week compared to Norditropin\u00ae once a day. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04970654. Accessed January 12, 2023."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/cen.13409","volume":"87","author":"Battelino","year":"2017","journal-title":"Clin Endocrinol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"e2717","DOI":"10.1210\/clinem\/dgac220","volume":"107","author":"Deal","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1159\/000524600","volume":"95","author":"Horikawa","year":"2022","journal-title":"Horm Res Paediatr"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.1210\/clinem\/dgab529","volume":"106","author":"Thornton","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"e2367","DOI":"10.1210\/clinem\/dgab016","volume":"106","author":"Bidlingmaier","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1530\/EJE-21-1167","volume":"187","author":"Kildemoes","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s40262-018-0662-5","volume":"58","author":"Juul","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1210\/clinem\/dgaa775","volume":"106","author":"Juul Kildemoes","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"bvad115","DOI":"10.1210\/jendso\/bvad115","volume":"7","author":"Kildemoes","year":"2023","journal-title":"J Endocr Soc."},{"key":"ref51","doi-asserted-by":"publisher","first-page":"bvac117","DOI":"10.1210\/jendso\/bvac117","volume":"6","author":"Maniatis","year":"2022","journal-title":"J Endocr Soc"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1159\/000524003","volume":"95","author":"Maniatis","year":"2022","journal-title":"Horm Res Paediatr"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"980979","DOI":"10.3389\/fendo.2022.980979","volume":"13","author":"Miller","year":"2022","journal-title":"Front Endocrinol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"e2121","DOI":"10.1210\/clinem\/dgz149","volume":"105","author":"Miller","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"e2680","DOI":"10.1210\/clinem\/dgac217","volume":"107","author":"Maniatis","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"ref56","unstructured":"Miller B, Savendahl L, Hickman K, et al. A long-acting growth hormone module for paediatric growth hormone deficiency in the Global Registry For Novel Therapies In Rare Bone & Endocrine Conditions \u2013 The GloBE-Reg LAGH Study. Available from: https:\/\/www.karger.com\/Article\/Pdf\/525606. Accessed April 13, 2023."},{"key":"ref57","doi-asserted-by":"publisher","first-page":"781","DOI":"10.2147\/PPA.S239196","volume":"14","author":"McNamara","year":"2020","journal-title":"Patient Prefer Adherence"},{"key":"ref58","unstructured":"Food and Drug Administration. Highlights of prescribing information for Skytrofa. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761177lbl.pdf. Accessed May 04, 2023."},{"key":"ref59","unstructured":"European Medicines Agency. Ngenla: SmPC. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ngenla-epar-product-information_en.pdf. Accessed May 04, 2023."},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Rivolo S, Loftus J, Peter B, et al. Cost-effectiveness and cost-utility analysis of somatrogon once-weekly injectable vs. daily growth hormones for treating pediatric growth hormone deficiency. Poster EE27. Poster presented at: Annual Meeting of ISPOR Europe; 2022. Vienna, Austria.","DOI":"10.1016\/j.jval.2022.09.280"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Mehl A, Goh A, Gupta S. Cost-effectiveness of once-daily somatropin from Sandoz versus once-weekly somatrogon for the treatment of growth hormone deficiency in children and adolescents. Poster EE589. Poster presented at: Annual Meeting of ISPOR Europe; 2022. Vienna, Austria.","DOI":"10.1016\/j.jval.2022.09.828"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1210\/jc.2013-4159","volume":"99","author":"Patterson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ghir.2006.03.002","volume":"16","author":"Darzy","year":"2006","journal-title":"Growth Hormone IGF Res"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"866295","DOI":"10.3389\/fped.2022.866295","volume":"10","author":"He","year":"2022","journal-title":"Front Pediatr"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1365-2265.2005.02404.x","volume":"64","author":"Jenkins","year":"2006","journal-title":"Clin Endocrinol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"P35","DOI":"10.1530\/EJE-21-1186","volume":"186","author":"Boguszewski","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"ref67","unstructured":"ClinicalTrials.gov. Investigating efficacy and safety of once-weekly NNC0195-0092 (somapacitan) treatment compared to daily growth hormone treatment (Norditropin\u00ae Flexpro\u00ae) in growth hormone treatment na\u00efve pre-pubertal children with growth hormone deficiency. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02616562?draw=2. Accessed April 13, 2023."}],"container-title":["Drug Design, Development and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=96505","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=96505","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T01:50:24Z","timestamp":1706925024000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/developments-in-the-management-of-growth-hormone-deficiency-clinical-u-peer-reviewed-fulltext-article-DDDT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":67,"URL":"https:\/\/doi.org\/10.2147\/dddt.s315172","relation":{},"ISSN":["1177-8881"],"issn-type":[{"value":"1177-8881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]}}}